ABSTRACT
The efficacy of specific and substitute markers of hepatitis C was compared in donor blood screening. 2615 blood donors were examined using two EIA kits for detection of HCV antibodies. The presence of nonspecific markers of non-A non-B hepatitis was also checked. 1.3% of the donors were found to carry HCV antibodies. This necessitates donor blood testing for anti-HCV antibodies using EIA. Such measure reduces three-fold the risk of the virus transmission with blood components and preparations. The preference should be given to more sensitive test systems of the second generation, whereas less sensitive, but more specific, test systems are more valuable for accurate diagnosis and treatment effects assessment in HCV infection. It would be appropriate to perform compulsory examinations for HCV infection in medical staff. This will entail efforts on development of the infection diagnostic verification criteria and preventive measures.
